Background and Objectives Plasma transfusions are a frequent treatment worldwide, but many studies have reported a wide variation in the indications to transfuse. Recently, an international paediatric study also showed wide variation in frequency in the use of plasma transfusions: 25% of the centres transfused plasma to >5% of their patients, whereas another 25% transfused plasma to <1% of their patients. The objective of this study was to explore the factors associated with different plasma transfusion practices in these centres.
Introduction
little quality evidence-based data exist to guide clinicians with regard to appropriate indications for plasma transfusion [3] .
This lack of evidence seems to have led to a wide variation in plasma transfusions practices. A national epidemiological study in UK adult critical care reported a wide range in plasma indications as well an important variation in plasma dose [4] . A scenario-based survey of 187 paediatric critical care physicians also showed a wide variation in the indications to plasma transfusions [5] . There is also an important variation in plasma transfusion practices among different countries, as plasma represents 17Á5% of all transfusions in the United States of America [6] , but only 12Á5% in France [7] and 12Á3% in Switzerland [8] . Furthermore, over the last 5 years, the consumption has been stable in the United States of America (from 17Á4% in 2008 to 17Á5% in 2013) , whereas it has slightly increased in France (from 11Á4% in 2008 to 12Á5% in 2013) and has decreased in Switzerland (from 16Á2% in 2008 to 12Á3% in 2013) . We recently conducted an observational study on plasma transfusions in 101 centres from 21 countries [9] . We reported significant heterogeneity in plasma use: whereas a 25% of the centres transfused plasma to > 5% of their patients, another 25% transfused plasma to <1% of their patients. Therefore, there seems to be a wide variation in the utilization of plasma transfusions, but there is no information on the reasons for this observation.
Consequently, the objective of this study was to explore a range of factors and beliefs associated with plasma transfusion for critically ill children at all centres, and to compare the results for the different practices of plasma transfusion between those centres with the highest and the lowest rate of plasma transfusions.
Material and methods

Study design
This survey used an online questionnaire.
Study population
The questionnaire was mailed to 101 paediatric critical care physicians from 21 countries, practicing in academic (PICUs) and who had participated in a large international point-prevalence study on plasma transfusions [9] . The latter study's objectives were to identify patient characteristics and to characterize indications leading to plasma transfusions in critically ill children as well as to assess the effect of plasma transfusions on coagulation tests. This point-prevalence study showed that 34% of transfused patients were not bleeding and had no planned procedure. Additionally, in most patients, coagulation tests were not sensitive to increased coagulation factor content resulting from plasma transfusion.
Development of questionnaire
Determinants potentially affecting transfusion practices were first identified through consultation with eight experts in paediatric critical care, haematology, and transfusion practice, and all members of the study steering committee. Four different areas were recognized and addressed in the survey: (1) beliefs regarding the efficacy of plasma transfusion (ability to prevent or stop bleeding, ability to improve abnormal coagulation tests, risks relating to nosocomial infections and acute lung injury, etc.); (2) patient case-mix at each unit (proportion of surgical, cardiac or trauma patients, proportion of trauma patients, proportion of patients on extracorporeal support, predicted and observed mortality, etc.); (3) characteristics of each unit (number of beds, number of critical care physicians, open vs. closed unit model (prescriptions done by primary physicians vs. only by critical care physicians), in-house critical care physician attendance at night, etc.); and (4) support from the local transfusion service (involvement of a blood banker or haematologist in reviewing the decision to transfuse, computerized ordering process requiring the physician to justify the transfusion, etc.).
We decided to define mild, moderate and severe coagulopathy as an international normalized ratio (INR) below 1Á5, between 1Á5 and 2Á5, and above 2Á5, respectively, and/or activated partial thromboplastin time (aPTT) below 60, between 60 and 80, and above 80, respectively.
Formatting and pretesting of questionnaire
The survey instrument was developed in English by two authors (OK and SS) and was formatted using a website (www.surveymonkey.com). We first ensured the clarity of the questionnaire, its relevance, its completeness, and its accuracy by testing it on five co-authors who were not directly involved in the phrasing of the questions (PD, AS, PCS, MT and SL). Some modifications were suggested, and changes were made. The survey is available as an online supplemental file.
Administration of the questionnaire
The survey administration was carried out according to the principles of Dillman [10] and the recommendation of Burns [11] . The first email was sent in February 2016, and two reminder mails were sent 2 and 4 weeks later.
Statistical analysis
Binary and multiple choice results are presented as proportions. Results from the 7-point Likert scale were categorized into 'disagree' or 'decreases the likelihood' (1 and 2), 'intermediate opinion' (3, 4, and 5) , and 'agree' or 'increases the likelihood' (6 and 7) . Continuous results are presented as median and interquartile range (IQR).
The participating centres were categorized as having high, intermediate and low rates of plasma transfusion according to the proportion of transfused patients in the observational study, that is >75th percentile, between the 25th and 75th percentile, and < the 25th percentile, respectively. Differences between the centres with high and low rates of plasma transfusion were evaluated using the Mann-Whitney U-test. Differences between the centres from Europe, North America and rest of the world were evaluated using the Kruskal-Wallis test.
Differences were considered statistically significant when a two-sided a level was <0Á05. No adjustments were made for multiple comparisons, as the different questions are not independent and as this would increase the risk of type II errors. All statistical analyses were performed with SPSS version 22 for Mac (SPSS, Chicago, IL, USA).
Results
The participation rate was 82% (83/101). Respondents were from 21 countries: 57% from Europe, 34% from North America and 9% from the rest of the world (Australia, Chile, Japan, New Zealand and Saudi Arabia). The median size of the participating PICUs was 13 beds (IQR: [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The median number of admissions per year was 700 (IQR: 400-1025). The median mortality rate was 4 (IQRP: 2-5). 36% of the centres did not offer ECMO, 29% had <10 ECMO runs per year, and 35% had >10 ECMO runs per year. 68% of the centres treated patients with liver failure and/or liver transplants. However, the median number of these liver patients with liver failure and/or liver transplants was only 4 per year (IQR: 2-10).
Overall beliefs on the benefits and harm of plasma transfusions
While only 27% of the respondents agreed that plasma transfusions can prevent bleeding, 43% agreed that they can stop bleeding. 29% agreed that they can improve moderately abnormal coagulation tests (Fig. 1) . 95% of the respondents agreed that plasma transfusions should not be used as volume expanders.
37% of the respondents thought that plasma transfusions are associated with increased risk of adverse reactions, such as increased risk of acute respiratory distress syndrome (ARDS), circulatory overload and nosocomial infection.
Indications for plasma transfusion
When coagulation tests are only mildly abnormal (INR < 1Á5 and aPTT < 40), even significant bleeding (3 ml/kg through a thoracocentesis drain) would not prompt plasma transfusion for 62% of the respondents, and a 29% would wait until the INR is >2Á5 to transfuse plasma (Table 1) .
When coagulation tests are severely abnormal (INR > 2Á5 and/or aPTT > 80), significant bleeding would prompt plasma transfusion for 71% of the respondents, but only 17% would transfuse plasma if the bleeding was minor. Moderate bleeding and critical bleeding, as well as an INR > 2Á5, were reported to increase the likelihood of plasma transfusion, whereas an INR < 1Á5 and a previous reaction to plasma transfusion were reported to decrease the likelihood of plasma transfusion (Fig. 2) . Hypovolaemia, mild bleeding, thrombocytopenia, anaemia and hypoxaemia were reported not to affect the likelihood of plasma transfusion.
Beliefs on predictive value of coagulation tests
Altogether, 30% of the respondents believed that coagulation tests could reliably predict bleeding, although there were differences among the stated predictability of different tests: 37% of the respondents believed that INR could predict bleeding, 34% thromboelastographic (TEG) or thromboelastometric (ROTEM) tests, 29% aPTT, 27% prothrombin time (PT) and 22% fibrinogen (P = 0Á01, Fig. 3) .
Respondents who believed that INR predicted bleeding were more likely to think that plasma transfusions can prevent bleeding (P = 0Á01), plasma transfusions can stop bleeding (P = 0Á02), plasma transfusions can improve mildly abnormal coagulation tests (P = 0Á001), plasma transfusions are an appropriate treatment for patients at risk of postop bleeding and with mild coagulopathy (P = 0Á02), and that plasma transfusions do not induce acute respiratory failure (P < 0Á001). However, there was no association between beliefs on predictive value of coagulation tests and physicians' or centres' demographics.
Local transfusion service and policies
Forty-eight per cent of the centres allowed only their physicians trained in critical care to prescribe plasma transfusions. However, other centres also allowed anaesthesiologists (31%), surgeons (29%), cardiac surgeons (28%) and haematologists (24%) to directly prescribe plasma transfusion for patients in the PICU. 60% of the centres required junior physicians (residents or fellows) to seek supervision by board-certified critical care physicians in order to prescribe plasma transfusion. Only 12% of the centres had a written protocol to guide plasma transfusions among which 50% did not update their protocol within a 2-year period. 90% of the protocols used INR as an indicator to plasma transfusion, 30% used PT, 60% used aPTT, and 40% also used TEG or ROTEM.
Sixty-six per cent of the centres had to justify plasma prescription to the blood bank or transfusion services, while ordering the plasma unit. However, these individuals rarely seemed to challenge a request for plasma which was reported in <6% of the centres.
Seventy-five per cent of the centres did not carry out any retrospective review regarding the use of plasma transfusions in their centre. Of those centres that undertook regular audit, 50% had this review at least every 3 months. Blood bank staff or transfusion services were involved in 71% of the reviews, haematologists in 42%, critical care physicians in 33%, quality officers in 19% and anaesthesiologists in 5%.
Comparison between centres with higher and lower rates of plasma transfusions
Hypovolaemia and mildly abnormal coagulation tests were more frequently believed to be appropriate indications to plasma transfusions in centres with a higher rate of plasma transfusions (24 vs. 14%, P = 0Á02 and 5 vs. 0%, P = 0Á04, respectively). These centres were more frequently situated in Europe (30 vs. 19%, P = 0Á04).
There were no other statistically significant differences between centres with high and low rates of plasma transfusions, in terms of case-mix (proportion of cardiac surgery, extracorporeal life support, etc.), PICU characteristics (number of beds, number of admissions per year, etc.) or plasma transfusion policies (Table 2 ). However, the centres with lower plasma transfusion rates tended to have less positive views on plasma transfusions (lower ability to stop bleeding, higher risk of transfusion associated nosocomial infections and acute respiratory failure), and more doubts that coagulation tests could predict bleeding. Furthermore, the centres with lower plasma transfusion rates tended to be larger and have fewer cardiac surgery admissions. Finally, there was a trend suggesting that PICUs with senior physicians attending during the night-time and supervision of prescriptions by junior physicians have lower plasma transfusion rates.
Barriers to changing plasma transfusion practices
A majority of the respondents reported that the lack of high-quality data to motivate practice change was the most important barrier to changing plasma transfusion practices (Table 3) .
Discussion
The results of this survey highlight several issues pertaining to plasma transfusion practices and emphasize the very divergent views on the benefits and harms of plasma transfusion.
Our survey showed that many respondents believe that plasma transfusions can both prevent and stop bleeding as well as correct mildly abnormal coagulation tests. However, there are only a few large randomized controlled trials, in very specific clinical settings, that have evaluated the effectiveness of plasma to prevent or stop bleeding. In the first trial, the Northern Neonatal Nursing Initiative (NNNI) Trial Group randomized 776 neonates to plasma or to volume expanders (gelofusine or dextrosesaline) and did not show any differences in the prevention of intraventricular haemorrhage [12] . More recently, the PROPPR trial recruited adults with severe trauma and major bleeding, and did not identify that mortality was affected by higher doses of plasma and platelet transfusions [13] . Etemadrezaie et al. [14] randomized 90 adults with severe closed head injury to receive plasma transfusions vs. normal saline and of note reported that new intracerebral haematomas in follow-up CT scans were more common in the plasma transfusion group vs. the normal saline group. Recently, M€ uller et al. [15] randomized critically ill adults with INR between 1Á5 and 3Á0 and who required a procedure to receive prophylactic plasma transfusion vs. normal saline. The rate of bleeding events was similar in both groups, supporting the view that plasma transfusion does not prevent bleeding events, although the study failed to recruit to target. In general, data from both adult and paediatric populations indicate that plasma transfusions fail to correct mildly abnormal coagulation tests (INR < 2Á5) [9, 16, 17] . Therefore, most of the perceived benefits of plasma transfusions are not based on solid evidence. In our study, 30% of the respondents believe that routinely used coagulation tests can predict bleeding. These physicians were more like to also believe that plasma transfusions could prevent or stop bleeding. However, many studies show that abnormal coagulation tests are not associated with increased risk of bleeding in association with various procedures (angiography, bronchoscopy, direct and transjugular liver biopsy and thoracocentesis) [18] . A recent randomized controlled trial, conducted in critically ill adults with INR between 1Á5 and 3 undergoing invasive procedures, has shown that coagulation tests and individual coagulation factor levels were similar in patients regardless of whether bleeding occurred [19] . Given that 41% of the respondents identified the lack of accurate tests to predict bleeding as a major barrier to improving plasma transfusion practices, one avenue of research should evaluate the development of new and reliable strategies to improve the identification of patients at risk of bleeding as a priority.
Our survey indicates that only 37% of the respondents believe that plasma transfusions are associated with adverse effects, and that by implication plasma transfusion is a very safe intervention. However, observational data in both adults and children indicate that plasma transfusions are associated with more nosocomial infections [20] , more respiratory failure [21] [22] [23] , more multiple organ dysfunction [20, 23] , increased PICU length of stay [20] and higher mortality [24] . These associations could be due to indication bias and may not actually reflect increased risk with plasma transfusion. Haemovigilance studies also show that plasma transfusions are frequently associated with transfusion related acute lung injury (TRALI), an eightfold increased risk compared to that associated with red cell transfusion [25] .
Overall, the survey was not able to identify factors associated with high vs. low plasma transfusion rates although this may have been influenced by demographic factors. Centres transfusing more frequently tend to be located in Europe, and were more often inclined to believe that hypovolaemia and mildly abnormal coagulation tests were appropriate indications for plasma transfusion. Although the patient case-mix and PICU characteristics were not significantly different between centres with high and low plasma transfusion rates, there were trends that suggested that larger PICUs with senior physicians attending during the night-time and supervision of prescriptions by junior physicians might be important elements that favour more restrictive plasma transfusion. However, this might also suggest that other factors not captured by this survey could be relevant; these might include multidisciplinary training on blood transfusion issues or unofficial policies affecting local practice. It is also possible that there is an association between the PICU characteristics (number of beds, inhouse senior physicians) are different in Europe and in North America. Due to the small sample size, this was not evaluated in a multiple regression model.
Certain limitations associated with the conduct of this survey must be recognized. Firstly, the small sample size and the substantial heterogeneity of the replies received may explain the fact that there were few statistically significant differences between centres with high and low transfusion rates. Secondly, a selection bias may have occurred given that the participating centres represented a small proportion of the PICUs existing worldwide who were willing to participate in the original observational study. Therefore, it is not known whether the answers obtained from those sites who participated can be generalized to other centres.
Our results suggest that there are very divergent views on the benefits and harms of plasma transfusions. The next step should focus on educational and training objectives that would lead to more evidence-based practice in paediatric critical care. These interventions should certainly be scientifically evaluated.
In conclusion, this survey assessed the beliefs of paediatric critical care physicians on plasma transfusions. The most striking observation resulting from this survey is the great diversity of opinion existing among paediatric physicians with regard to the potential benefits and risks of plasma. This clearly highlights the importance of implementing educational initiatives and the need for stronger evidence from future randomized controlled trials.
